Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
Hong Kong-listed Sino Biopharmaceutical said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million.